Stelmakh Edward — SEC insider filings
SEC reporting owner CIK 1887046. 22 insider filings on record with FilingPulse; latest filed 2026-08-24.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2021-10-13 to 2026-08-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 3,000 shares, $46,290 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 1,388 shares, $18,752 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 45.
- Largest priced transaction: purchase of 3,000 shares @ $15.43 ($46,290) in OptimizeRx Corp, filed 2022-08-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| OptimizeRx Corp (OPRX) | Chief Finance & Strat Officer | 22 | 1 leg · 3,000 sh · $46,290 | 1 leg · 1,388 sh · $18,752 | 45 |
Insider filings — Stelmakh Edward
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-24 | 4 | OptimizeRx Corp (OPRX) | Tax withholding (F): 1,381 @ $7.71 | EDGAR |
| 2025-12-23 | 4/A | OptimizeRx Corp (OPRX) | Option exercise (M): 5,237 @ $0 · Tax withholding (F): 1,388 @ $13.51 · Option exercise (M): 5,237 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | OptimizeRx Corp (OPRX) | Tax withholding (F): 3,658 @ $12.74 | EDGAR |
| 2025-12-22 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 5,237 @ $0 · Sale (S): 1,388 @ $13.51 · Option exercise (M): 5,237 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 16,623 @ $0 · Tax withholding (F): 4,406 @ $18.75 · Option exercise (M): 16,623 (derivative) @ $0 | EDGAR |
| 2025-08-25 | 4 | OptimizeRx Corp (OPRX) | Grant/award (A): 15,625 @ $0 · Grant/award (A): 35,156 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | OptimizeRx Corp (OPRX) | Tax withholding (F): 2,156 @ $6.64 | EDGAR |
| 2024-12-27 | 4/A | OptimizeRx Corp (OPRX) | Grant/award (A): 0 @ $0 | EDGAR |
| 2024-12-27 | 4 | OptimizeRx Corp (OPRX) | Grant/award (A): 41,408 @ $0 · Grant/award (A): 77,742 (derivative) @ $0 | EDGAR |
| 2024-12-20 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 5,237 @ $0 · Tax withholding (F): 1,316 @ $4.75 · Option exercise (M): 5,237 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 8,222 @ $0 · Tax withholding (F): 2,066 @ $6.63 · Option exercise (M): 8,222 (derivative) @ $0 | EDGAR |
| 2024-10-07 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 16,622 @ $0 · Tax withholding (F): 4,177 @ $7.83 · Option exercise (M): 16,622 (derivative) @ $0 | EDGAR |
| 2024-04-24 | 4 | OptimizeRx Corp (OPRX) | Grant/award (A): 7,083 @ $0 | EDGAR |
| 2024-04-22 | 4/A | OptimizeRx Corp (OPRX) | Tax withholding (F): 3,539 @ $15.17 | EDGAR |
| 2024-04-22 | 4/A | OptimizeRx Corp (OPRX) | Option exercise (M): 8,221 @ $0 | EDGAR |
| 2024-02-21 | 4 | OptimizeRx Corp (OPRX) | Grant/award (A): 15,711 (derivative) @ $0 · Grant/award (A): 15,711 (derivative) @ $0 | EDGAR |
| 2023-10-12 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 8,221 @ $0 · Option exercise (M): 6,155 @ $0 · Tax withholding (F): 2,066 @ $7.15 · Option exercise (M): 8,221 (derivative) @ $0 · Option exercise (M): 8,221 (derivative) @ $0 | EDGAR |
| 2023-10-06 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 16,662 @ $0 · Tax withholding (F): 4,117 @ $7.06 · Option exercise (M): 16,662 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | OptimizeRx Corp (OPRX) | Option exercise (M): 8,221 @ $0 · Tax withholding (F): 6,539 @ $15.17 · Option exercise (M): 8,221 (derivative) @ $0 | EDGAR |
| 2022-10-05 | 4 | OptimizeRx Corp (OPRX) | Grant/award (A): 49,867 (derivative) @ $0 · Grant/award (A): 97,637 (derivative) @ $0 | EDGAR |
| 2022-08-17 | 4 | OptimizeRx Corp (OPRX) | Purchase (P): 3,000 @ $15.43 | EDGAR |
| 2021-10-13 | 4 | OptimizeRx Corp (OPRX) | Grant/award (A): 24,664 (derivative) @ $0 · Grant/award (A): 25,191 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-10-07 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1887046 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs